A Phase II, Single Arm, Open Label Study of Treatment-Free Remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients After Achieving Sustained MR4.5 on Nilotinib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENESTop
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 01 Jul 2019 According to a Novartis media release, data from this trial were presented at the 24th Congress of the European Hematology Association (EHA) 2019.
- 01 Jul 2019 Results presented in the Novartis media release.
- 13 Jun 2019 Results presented in a Novartis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History